The Grünenthal Group Enters into Exclusive Agreement with Horizon Pharma for Commercialization of DUEXIS® in Latin America

The Grünenthal Group today announced that it has entered into an exclusive agreement with Horizon Pharma, Inc.

for the commercialization of DUEXIS® in Latin America. "We are excited about strengthening our existing product portfolio in Latin America with DUEXIS®," said Jose Maria Mora, acting Executive Vice President, Grünenthal Latin America. "The agreement with Horizon Pharma is the first strategic step for the complete coverage of the Latin American market with our pain portfolio and shows that we are an attractive partner to other pharmaceutical companies. This is very important for the long-term success of the Grünenthal business in Latin America." "As this is our first out-license of DUEXIS® outside the U.S., we are especially pleased to partner in Latin America with Grünenthal, a worldwide leader in the promotion of pain products," said Timothy P. Walbert, Chairman, President and Chief Executive Officer, Horizon Pharma.